Non-Alcoholic Steatohepatitis Clinical Trials Market Report

Dublin, 22 Feb. 2022 (GLOBE NEWSWIRE) — The “Non-Alcoholic Steatohepatitis Clinical Trials Market Size, Share and Trends Analysis Report by Phase (Phase I, II, III, IV), by Plan Study (Interventional, Expanded Access), By Region (APAC, Europe) and Segment Forecasts Report, 2022-2030″ has been added to from offer.

The global non-alcoholic steatohepatitis clinical trial market size is expected to reach USD 4.2 billion by 2030, registering a CAGR of 6.5% over the forecast period.

Rising healthcare expenditure, obesity cases and prevalence of non-alcoholic steatohepatitis (NASH) are the growth factors of this market. Due to the COVID-19 pandemic, enrollment in new drug clinical trials for NASH patients has been halted, but people have turned to other means of data collection, such as virtual visits. Non-alcoholic steatohepatitis is fatty liver disease that causes scarring and damage to the liver.

NASH has no FDA-approved treatment and can go to the point where patients need liver transplants in extreme situations. NASH, like diabetes, is linked to obesity and high sugar diets. Some pharmaceutical companies are testing whether diabetes drugs could help NASH patients. However, the COVID-19 pandemic has thrown a wrench into every element of NASH clinical trials, from patient recruitment to intellectual property administration and safety oversight to data integrity. As clinical research monitors are not allowed to travel, remote electronic monitoring is a viable alternative to traditional on-site monitoring. Monitors could receive information from research locations by paper mail, email (allowing direct access to electronic medical records), or remote monitoring systems.

In December, the FDA issued guidelines urging the pharmaceutical industry to develop and confirm improved biomarkers for the diagnosis and progression of NASH. In many ways, breaking the biopsy barrier is important compared to a general lack of awareness of NASH, which is why it is essential that pharmaceutical companies invest in innovations (such as a variety of techniques for imaging) to ease this burden on the patient, and then persuade the FDA with positive data to accept these advances as appropriate endpoint markers for clinical trials.

Non-Alcoholic Steatohepatitis Clinical Trials Market Report Highlights

  • The phase III segment dominated the global market in 2021. These trials cost more than $100 million
  • The interventional study design segment held the largest revenue share in 2021. There were 84 ongoing interventional studies with patients enrolled in December 2019 to assess the therapeutic efficacy of NASH treatments
  • North America led the global market in 2021 owing to the increase in the number of NASH patients in the region
  • According to the US National Library of Medicine 2018, NASH cases in the US are expected to increase by 63% from 16.52 million to 27.00 million cases by 2030
  • Asia-Pacific is expected to register the fastest CAGR over the forecast period due to the increasing incidence of associated risk factors, such as obesity, type 2 diabetes (T2D), dyslipidemia and other metabolic diseases with substantial diagnostic improvements using ultrasound and biomarkers

Main topics covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Non-Alcoholic Steatohepatitis (NASH) Clinical Trials Market: Variables, Trends and Scope
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis Increase investments in pharmaceutical R&D Increase in the diabetic population and obesity Increase in health expenditure
3.2.2 Market Restraint Analysis Lack of awareness Barriers to registration Approval process for lethargic drugs
3.3 Mapping penetration and growth prospects
3.4 Impact of COVID-19 on the market
3.5 Analysis of major transactions and strategic alliances
3.6 NASH clinical trials: market analysis tools

Chapter 4 Non-Alcoholic Steatohepatitis (NASH) Clinical Trials Market: Phase Segment Analysis

Chapter 5 Non-Alcoholic Steatohepatitis (NASH) Clinical Trials Market: Study Design Segment Analysis

Chapter 6 Non-Alcoholic Steatohepatitis (NASH) Clinical Trials Market: Regional Analysis

Chapter 7 Company Profiles

  • Pfizer Inc.
  • Shire Plc
  • Novartis AG
  • Plc icon.
  • LabCorp
  • Allergan AG
  • Cadila Healthcare Ltd.
  • Eli Lily
  • Novo Nordisk
  • Glaxosmith Kline

For more information about this report visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

  • Global Non-Alcoholic Steatohepatitis Clinical Trials Market


Comments are closed.